Chrom	Start	End	Strand	GSC Myeloid Panel	ICC/WHO?	UHN Myeloid Panel	Illumina TrueSight Myeloid Panel	LOD list	Gene name	Description	Tier	FDA-approved drugs (OncoKB)	WHO classification	ICC classification	Most common fusion	Partner genes/ variants	Typical clinical and BM manifestations	Targeted therapy	Disease	Prognosis	Additional cytogenetics
chr9	130713043	130887675	plus	No	Yes	Yes	Yes	No	ABL1	Gene fusion	1A if fused with BCR, otherwise 3A	Nilotinib	Acute myeloid leukaemia with BCR::ABL1 fusion, (WHO, PMID: 35732831).	AML with t(9;22)(q34.1;q11.2)/BCR::ABL1§ = 20%, (ICC, PMID: 35767897).	BCR	NA	NA	NA	AML	Optical Genome Mapping detected a translocation t(9;22)(q34.1;q11.2) with a variant allele frequency (VAF) of [%]. The t(9;22)(q34.1;q11.2) is a recurrent abnormality resulting in a BCR::ABL1 fusion. In the context of AML it is considered to have an adverse prognosis according to the ELN 2022 (PMID: 35797463).	NA
chr1	179099329	179229677	minus	Expanded	No	Yes	No	No	ABL2	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr6	167826910	167972023	plus	No	No	Yes	No	No	AFDN	FUS	1A if fused to KMT2A, otherwise 3A	None	NA	NA	NA	NA	NA	NA	AML	Optical Genome Mapping detected a translocation t(6;11)(q27;q23.3) with a variant allele frequency (VAF) of [%]. The t(6;11)(q27;q23.3) is a recurrent abnormality resulting in a AFDN::KMT2A fusion. In the context of AML it is considered to have a adverse prognosis according to the ELN 2022 (PMID: 35797463).	NA
chr4	86935010	87141039	plus	No	No	Yes	No	No	AFF1	FUS	1A if fused to KMT2A, otherwise 3A	None	NA	NA	NA	NA	NA	NA	AML	Optical Genome Mapping detected a translocation t(4;11)(q21.3;q23.3) with a variant allele frequency (VAF) of [%]. The t(4;11)(q21.3;q23.3) is a recurrent abnormality resulting in a AFF1::KMT2A fusion. In the context of AML it is considered to have an adverse prognosis according to the ELN 2022 (PMID: 35797463).	NA
chrX	55009055	55030977	minus	Expanded	No	No	No	No	ALAS2	Exon, 7	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr2	29192773	29921586	minus	No	No	Yes	No	No	ALK	FUS	2	Lorlatinib	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr10	26973793	27100494	minus	No	Yes	Yes	No	No	ANKRD26	Mutated gene	1A	None	Myeloid neoplasms with germline predisposition and pre-existing platelet disorder, (WHO, PMID: 35732831).	Myeloid neoplasms with germline ANKRD26 mutation, (ICC, PMID: 35767897).	NA	NA	NA	NA	NA	NA	NA
chr20	32358330	32439319	plus	Core	Yes	Yes	Yes	Yes	ASXL1	Mutated gene	1A	None	Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related. Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis, defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2 (ICC, PMID: 35767897)., (ICC, PMID: 35767897).	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Optical Genome Mapping detected a [Rearrangements, copy number loss, disrupting insertions, deletions] on chromosome 20 involving the ASXL1 gene with a variant allele frequency of []. ASXL1 mutations frequently occur in myeloid malignancies and are associated with a poor prognosis (PMID: 36068610, 28179279,27069254). ASXL1 mutations in AML were an unfavorable prognostic factor as regards survival (median overall survival 15.9 months vs. 22.3 months; P=0.019), with a significantly lower complete response rate (61% vs. 79.6%; P=0.004) (PMID: 22058207). Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463).	Truncating ASXL1 mutations were present in 5.3% of AMLs (46/882) (PMID: 22058207)
chr14	96279194	96363341	minus	No	No	Yes	No	No	ATG2B	DUPminush	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr3	142449235	142578733	minus	Expanded	No	No	No	No	ATR	Exon, 33	2	Talazoparib + Enzalutamide	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr14	99169287	99272197	minus	No	Yes	Yes	No	No	BCL11B	Gene rearrangement	1A	None	Classification of T-ALL, (WHO, PMID: 35732831).	Early T-cell precursor ALLwith BCL11B rearrangement, (ICC, PMID: 35767897).	NA	NA	NA	NA	NA	NA	NA
chrX	40049815	40177329	minus	Core	Yes	Yes	Yes	Yes	BCOR	Mutated gene	1A	None	Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related. Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis. Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2 (ICC, PMID: 35767897)., (ICC, PMID: 35767897).	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Optical Genome Mapping detected a translocation t(X;17)(p11.4;q21.2) or [rearrangement, loss, insertion, deletion] of BCOR with a variant allele frequency (VAF) of [%]. The t(X;17)(p11.4;q21.2) is a rare, but recurrent variant RARA translocation resulting a BCOR::RARA fusion (PMID: 35797463). While PML::RARA fusions are considered to have a good prognosis the exact prognosis and response to therapy for variant RARA fusions in unclear. Correlation with other clinical and pathologic findings is recommended. Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463, 28179279,27069254).	NA
chrX	129982634	130058071	plus	No	No	Yes	Yes	Yes	BCORL1	LOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr22	23179704	23318037	plus	No	Yes	Yes	No	No	BCR	Gene fusion	1A if fused with ABL1, otherwise 3A	None	Acute myeloid leukaemia with defining genetic abnormalities; acute myeloid leukaemia with BCR::ABL1 fusion. , (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with t(9;22)(q34.1;q11.2)/BCR::ABL1§ = 20%. Classification of B-ALL; B-ALLwith t(9;22)(q34.1;q11.2)/BCR::ABL1, B-ALL, BCR::ABL1–like, ABL-1 class rearranged, B-ALL, BCR::ABL1–like, JAK-STAT activated, B-ALL, BCR::ABL1–like, NOS, (ICC, PMID: 35767897).	ABL1	NA	NA	NA	AML	Optical Genome Mapping detected a translocation t(9;22)(q34.1;q11.2) with a variant allele frequency (VAF) of [%]. The t(9;22)(q34.1;q11.2) is a recurrent abnormality resulting in a BCR::ABL1 fusion. In the context of AML it is considered to have an adverse prognosis according to the ELN 2022 (PMID: 35797463).	NA
chr12	51281037	51324174	minus	No	No	Yes	No	No	BIN2	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr15	90717346	90816166	plus	No	Yes	No	No	No	BLM	NA	1A	None	Subtypes of myeloid neoplasms associated with germline predisposition, Myeloid neoplasms with germline predisposition and potential organ dysfunction, (WHO, PMID: 35732831).	NA	NA	NA	NA	NA	NA	NA	NA
chr7	140730664	140924929	minus	Expanded	No	Yes	Yes	No	BRAF	GOF	3A	Vemurafenib + Atezolizumab + Cobimetinib	NA	NA	NA	NA	NA	NA	NA	The activating V600E BRAF mutation is found in 50% of Langerhans cell histiocytosis (LCH) myeloid neoplasms (PMID: 34996063) and is consdered a molecular marker of hairy cell leukemia (HCL) present in >95% of cases (WHO, PMID: 35732829). BRAF mutations are found in <1% of MDS cases "with clinical implications that are likely similar to those of NRAS mutations" (Lindsley (2013) PMID:22934674)	NA
chr19	12938608	12944489	plus	Core	No	Yes	Yes	No	CALR	LOF	1B for altered C terminals in MPN, 3A for AML	None	NA	NA	NA	NA	NA	NA	AML, MPN	CALR mutations are identified in 20-25% of MF and ET cases though rarely identified in de novo AML cases. PMF patients with a CALR mutation have improved survival compared to either JAK2-mutant or triple-negative patients (NCCN Guidelines - MPN 2023) and ET patients with a CALR mutation have a lower-risk of thrombosis compared to JAK2-mutated ET (NCCN Guidelines - MPN 2023). The predictive and prognostic significance of CALR in AML remain uncertain.	NA
chr16	88874857	88977207	minus	No	No	Yes	No	No	CBFA2T3	FUS	1A if fused to RUNX1 or GLIS2, otherwise 3A	None	NA	NA	NA	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(16;21)(q24.3;q22.1) or inv(16)(p13.3q24.3) with a variant allele frequency (VAF) of [%]. This is a rare, recurrent abnormality resulting in a RUNX1::CBFA2T3 or CBFA2T3::GLIS2 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.	NA
chr16	67028984	67101058	plus	No	Yes	Yes	No	No	CBFB	Gene fusion	1A if fused with MYH11, otherwise 3A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with CBFB::MYH11 fusion., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11 = 10%., (ICC, PMID: 35767897).	NA	NA	NA	NA	AML	Optical Genome Mapping detected a translocation inv(16)(p13.1q22) or t(16;16)(p13.1;q22) which is a recurrent abnormality resulting in a CBFB::MYH11 fusion. In the context of AML it is considered to have a favourable favorable prognosis mainly based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. Concurrent KIT and/or FLT3 gene mutation does not alter risk categorization (ELN, PMID: 35797463)	NA
chr11	119206338	119308149	plus	Core	No	Yes	Yes	No	CBL	LOF	1B for MPN, 2 for AML, 3A for MDS	None	NA	NA	NA	NA	NA	NA	AML, MDS, MPN, AA	CBL mutations occur in 1-3% of AML cases, 1-2% of all MPN caes, 5% of MDS cases and 10-15% in MDS/MPN overlap syndromes (e.g. CMML) (NCCN Guidelines - MDS 2023). Preclinical studies have shown leukemic cells expressing mutant CBL and wild-type FLT3 are sensitive to FLT3 inhibition (Weisberg (2019) PMID: 31309543; Weisberg (2020) PMID: 31943762). The predictive and prognostic significance of CBL mutations in MDS remain uncertain. CBL mutations are associated with inferior overall survival in MF patients post allogeneic SCT (NCCN Guidelines - MPN 2022).	NA
chr9	120388874	120580167	minus	No	No	Yes	No	No	CDK5RAP2	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr9	21967751	21974857	minus	No	No	Yes	Yes	Yes	CDKN2A	LOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr13	27960917	27969315	minus	No	No	Yes	No	No	CDX2	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr19	33299934	33302534	minus	Core	Yes	Yes	Yes	No	CEBPA	LOF	1A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with CEBPA mutation. Subtypes of myeloid neoplasms associated with germline predisposition; Myeloid neoplasms with germline predisposition without a pre-existing platelet disorder or organ dysfunction., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with in-frame bZIP CEBPA mutations = 10%. Hematologic neoplasms with germline predisposition without a constitutional disorder affecting multiple organ systems; Myeloid neoplasms with germline CEBPA mutation (ICC, PMID: 35767897)., (ICC, PMID: 35767897).	NA	NA	NA	NA	AML (=10% blasts)	Optical Genome Mapping detected a ______ on chromosome 19 involving the CEBPA gene with a variant allele frequency of []. The prognostic significance of CEPBA structural variants is currently unclear. Correlation with other clinical and pathologic findings is required.	NA
chr22	28687743	28741834	minus	Expanded	No	No	No	No	CHEK2	NA	3A	Talazoparib + Enzalutamide	NA	NA	NA	NA	NA	NA	NA	CHEK2 was identified as the most frequent germline mutated gene in a cohort of 391 adult patients with AML. However, more data is warranted to clarify the role of germline CHEK2 mutations in the development of myeloid malignancies (Freiman et al. 2022)	NA
chr9	121074954	121177610	plus	No	No	Yes	No	No	CNTRL	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr16	3725053	3880713	minus	No	No	Yes	No	No	CREBBP	FUS	1A if fused to KAT6A, otherwise 3A	None	NA	NA	NA	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(8;16)(p11.2;p13.3) with a variant allele frequency (VAF) of [%]. The t(8;16)(p11.2;p13.3) is a rare, recurrent abnormality resulting in a KAT6A::CREBBP fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). KAT6A::CREBBP associated with adverse risk category (ELN, PMID: 35797463).	NA
chrX	1190489	1212649	minus	No	No	Yes	No	No	CRLF2_chrX	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chrY	1190489	1212649	minus	No	No	Yes	No	No	CRLF2_chrY	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr1	36466042	36483314	minus	Core	No	Yes	Yes	No	CSF3R	GOFminush	3A for AML/MDS, activating mutation could be 2 for some MPNs	None	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	CSF3R mutations are identified in approximately 2-4% of AML cases and 1-2% of MDS cases. Activating mutations of the CSF3R protein lead to constitutive JAK-STAT pathway signalling (Zhang (2017) PMID:28439110). The predictive and prognostic significance of CSF3R mutations in AML remain uncertain. Activating changes in CSF3R are a diagnostic feature of chronic neutrophilic leukemia (CNL) (WHO PMID: 31769070) but may also be identified in a subset of atypical chronic myeloid leukemia (aCML) and chronic myelomonocytic leukemia (CMML) (NCCN Guidelines - MDS 2021; Pardanani (2013) PMID:23604229, Gotlib (2013) PMID:23896413; Maxson (2013) PMID:23656643). Activating CSF3R changes are associated with more aggressive disease in CNL and sensitivity to ruxolitinib (Dao (2020) PMID:31880950, Szuber (2020) PMID:31769070). Emerging data suggests that aCML patients with CSF3R or JAK2 mutations may respond to ruxolitinib therapy in combination with HMAs (hypomethylating agent) (NCCN Guidelines - MDS 2021).	NA
chr5	138753424	138935034	plus	No	No	Yes	No	No	CTNNA1	LOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr7	101816006	102258233	plus	Expanded	No	Yes	Yes	Yes	CUX1	LOF	3A	None	NA	NA	NA	NA	NA	NA	NA	CUX1MT were present in 4% of chronic myeloid neoplasms (PMID: 31320321)The CUX1 gene, located on 7q22.1, has been characterized genetically as a haplo-insufficient tumor suppressor gene (PMID: 31320321).	NA
chr5	177511577	177516961	minus	Expanded	Yes	Yes	No	No	DDX41	LOF	1A	None	Subtypes of myeloid neoplasms associated with germline predisposition; Myeloid neoplasms with germline predisposition without a pre-existing platelet disorder or organ dysfunction, (WHO, PMID: 35732831).	Hematologic neoplasms with germline predisposition without a constitutional disorder affecting multiple organ systems; Myeloid or lymphoid neoplasms with germline DDX41 mutation, (ICC, PMID: 35767897).	NA	NA	NA	NA	NA	NA	NA
chr6	18223860	18264548	minus	No	Yes	Yes	No	No	DEK	Gene fusion	1A if fused to NUP214, otherwise 3A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with DEK::NUP214 fusion., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with t(6;9)(p22.3;q34.1)/DEK::NUP214 = 10%., (ICC, PMID: 35767897).	NA	NA	NA	NA	AML	Optical Genome Mapping detected a translocation t(6;9)(p22.3;q34.1) with a variant allele frequency (VAF) of [%]. The t(6;9)(p22.3;q34.1) is a recurrent abnormality resulting in a DEK::NUP214 fusion. In the context of AML it is considered to have a adverse favorable prognosis according to the ELN 2022 (PMID: 35797463).	NA
chrX	154762742	154777689	plus	Expanded	No	No	No	No	DKC1	Exon, 9	3A	None	NA	NA	NA	NA	NA	NA	NA	DKC1 is used to identify telomere biology disorders (TBD) patients by affecting telomere structural integrity and maintenance specifically (PMID: 35524933). DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF-<U+03BA>B pathway. (PMID: 29901172)	NA
chr2	25227873	25341925	minus	Core	No	Yes	Yes	Yes	DNMT3A	LOF	3A	None	NA	NA	NA	NA	NA	NA	NA	DNMT3A mutations are identified in 15-25% of AML cases, 12-18% of MDS case and 7-10% of MPN cases. In AML, there is conflicting data on the prognostic significance of DNMT3A mutations and outcome may depend on co-occurring mutations and age (NCCN Guidelines - AML 2023). Although one study identified an association between DNMT3A mutations and a decreased overall survival in MDS (PMID:21415852), there is insufficient data on the prognosis and predictive significance of DNMT3A mutations in MDS. In one study, DNMT3A mutations were associated with a negative prognostic impact in CMML (PMID:27733013). The predictive and prognostic significance of DNMT3A in MPN remain unclear.	NA
chr5	158695919	159099916	minus	No	No	Yes	No	No	EBF1	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr5	138465478	138469303	plus	No	No	Yes	No	Yes	EGR1	LOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr19	18442662	18522070	minus	No	No	Yes	No	No	ELL	FUS	1A if fused to KMT2A, otherwise 3A	None	NA	NA	NA	NA	NA	NA	AML	Optical Genome Mapping detected a translocation t(11;19)(q23.3;p13.1) with a variant allele frequency (VAF) of [%]. The t(11;19)(q23.3;p13.1) is a recurrent abnormality resulting in a ELL::KMT2A fusion. In the context of AML it is considered to have a adverse favorable prognosis according to the ELN 2022 (PMID: 35797463).	NA
chr22	41092591	41180077	plus	No	No	Yes	No	No	EP300	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr19	11377206	11384314	minus	No	No	Yes	No	No	EPOR	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr9	95875691	96041092	plus	Expanded	No	No	No	No	ERCC6L2	Exons, 5,, 9,, 13,, 15	2	None	NA	NA	NA	NA	NA	NA	NA	Biallelic germ line ERCC6L2 variants strongly predispose to bone marrow failure (BMF) and myeloid malignancies, characterized by somatic TP53-mutated clones and erythroid predominance. The prognosis of MDS/AML in patients with ERCC6L2 germline variants is poor, especially when progression to acute erythroid leukemia is noted (PMID: 37091189).	NA
chr21	38380035	38498477	minus	No	No	Yes	No	No	ERG	FUS	1A if fused to FUS, otherwise 3A	None	NA	NA	NA	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(16;21)(p11.2;q22.2) with a variant allele frequency (VAF) of [%]. The t(16;21)(p11.2;q22.2) is a rare, recurrent abnormality resulting in a FUS::ERG fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.	NA
chr12	22625170	22690665	plus	No	No	Yes	No	No	ETNK1	GOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr21	38805183	38824954	plus	Expanded	No	No	No	No	ETS2	Exon, 2	2	None	NA	NA	NA	NA	NA	NA	NA	High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation (PMID: 30022221).	NA
chr12	11649674	11895377	plus	Core	Yes	Yes	No	Yes	ETV6	LOF	1A if fused to ABL1, MECOM, otherwise 3A	None	Subtypes of myeloid neoplasms associated with germline predisposition; Myeloid neoplasms with germline predisposition and pre-existing platelet disorder, (WHO, PMID: 35732831).	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions; Myeloid/lymphoid neoplasm with ETV6::ABL1, (ICC, PMID: 35767897).	MECOM, MNX1	GSX2, GSX1	NA	NA	NA	Optical Genome Mapping detected a translocation t(7;12)(q36.3;p13.2) or t(3;12)(q26.2;p13.2) or t(4;12)(q12;p13.2) or t(12;13)(p13.2;q12.2) with a variant allele frequency (VAF) of [%]. This is a rare, recurrent abnormality resulting in a ETV6::MNX1 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms or the ETV6::MECOM fusion. In the context of AML, the ETV6::MNX1 fusion is associated with an unclear, ETV6::MECOM fusion associated with adverse risk category (ELN, PMID: 35797463). The t(4;12)(q12;p13.2) and t(12;13)(p13.2;q12.2) are rare, recurrent abnormality resulting in a GSX2::ETV6 and ETV6::GSX1 fusions with unclear prognosis.	NA
chr22	29268267	29300521	plus	No	No	Yes	No	No	EWSR1	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr7	148807257	148884321	minus	Core	Yes	Yes	Yes	Yes	EZH2	LOF	1A	Tazemetostat	Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2 (ICC, PMID: 35767897)., (ICC, PMID: 35767897).	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)	NA
chr4	152321257	152535033	minus	No	No	Yes	Yes	No	FBXW7	LOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr2	218981086	218985184	minus	No	No	Yes	No	No	FEV	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr8	38400215	38468834	minus	Expanded	Yes	Yes	No	No	FGFR1	Gene rearrangement/fusion	1A	Pemigatinib	NA	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions; Myeloid/lymphoid neoplasm with FGFR1 rearrangement, (ICC, PMID: 35767897).	t(8;13)(p11.2;q12.1)/ ZMYM2::FGFR1	15 other partners including BCR (ZMYM2, TPR, RANBP2, LRRFIP1, SQSTM1, CUX1, TRIM24, FGFR1, HOOK3, CNTRL, FGFR1OP2, CPSF6, MYO18A, ERVK3-1, BCR)	Common: Extramedullary T-ALL/ LL with BM MPN-like or blast phase of MPN;	High rate of response to FGFR inhibitor such as pemigatinib, especially for cases in chronic phase	NA	Optical Genome Mapping detected a ____ translocation resulting in a ____:::FGFR1 fusion gene. The _____ fusion is a recurrent rearrangement seen in 8p11 Myeloproliferative Syndrome and may respond to targeted FGFR inhibitor(s). (PMID: 35767897).	NA
chr4	53377640	53460862	plus	No	No	Yes	No	No	FIP1L1	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr13	28003274	28100592	minus	Core	Yes	Yes	Yes	No	FLT3	Gene rearrangement/GOF	1A	Midostaurin + High Dose Chemotherapy	NA	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions; Myeloid/lymphoid neoplasm with FLT3 rearrangement (ICC, PMID: 35767897)., (ICC, PMID: 35767897).	t(12;13)(p13.2;q12.2)/ ETV6::FLT3	ZMYM2, TRIP11, SPTBN1, GOLGB1, CCDC88C, MYO18A, BCR, ETV6	T-ALL/LL or myeloid sarcoma with CEL-like or MDS/MPN BM features	Various responses to specific FLT3 inhibitors	NA	Optical Genome Mapping detected a translocation of the ETV6 gene (12p13.2) with the FLT3 gene (13q12.2) with a variant allele frequency of ___. The FLT3:: fusion is a rare, but recurrent rearrangement seen in myeloid and lymphoid neoplasia with eosinophilia and may respond to specific FLT3 inhibitors (PMID: 35767897).	NA
chr16	31180138	31191605	plus	No	No	Yes	No	No	FUS	FUS	1A if fused to ERG, otherwise 3A	None	NA	NA	NA	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(16;21)(p11.2;q22.2) with a variant allele frequency (VAF) of [%]. The t(16;21)(p11.2;q22.2) is a rare, recurrent abnormality resulting in a FUS::ERG fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.	NA
chrX	48786589	48794311	plus	Expanded	No	Yes	Yes	No	GATA1	FUS	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr3	128479427	128493201	minus	Core	Yes	Yes	Yes	Yes	GATA2	GOF/Fusion	1A if fused to MECOM, otherwise 3A	None	NA	Classification of AML with percentage of blasts required for diagnosis; AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2; MECOM(EVI1) = 10%. Hematologic neoplasms with germline predisposition associated with a constitutional disorder affecting multiple organ systems; Myeloid neoplasms with germline GATA2 mutation. Subtypes of myeloid neoplasms associated with germline predisposition; Myeloid neoplasms with germline predisposition and potential organ dysfunction., (ICC, PMID: 35767897).	NA	NA	NA	NA	AML	Optical Genome Mapping detected a t(3;3)(q21.3;q26.2). This is a recurrent abnormality resulting in a GATA2::MECOM(EVI1) fusion associated with adverse risk prognosis in the context of AML (PMID: 35797463).	NA
chr12	109929803	109996368	minus	No	No	Yes	No	No	GIT2	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr16	4316066	4339595	plus	No	No	Yes	No	No	GLIS2	FUS	1A if fused to CBFA2T3, otherwise 3A	None	NA	NA	NA	NA	NA	NA	NA	Optical Genome Mapping detected a translocation inv(16)(p13.3q24.3) with a variant allele frequency (VAF) of [%]. The inv(16)(p13.3q24.3) is a rare, recurrent abnormality resulting in a CBFA2T3::GLIS2 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.	NA
chr20	58891420	58911192	plus	No	No	Yes	Yes	No	GNAS	LOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr1	1785285	1891087	minus	No	No	Yes	No	No	GNB1	GOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr3	37243270	37366879	plus	No	No	Yes	No	No	GOLGA4	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr14	96363525	96387288	plus	No	No	Yes	No	No	GSKIP	DUPminush	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr7	75533297	75738941	minus	No	No	Yes	No	No	HIP1	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr17	55264960	55325187	plus	No	Yes	Yes	No	No	HLF	Mutated gene	1A	None	NA	Classification of B-ALL; B-ALL with HLF rearrangement, (ICC, PMID: 35767897).	TCF3; TCF4	NA	NA	NA	NA	Very poor	NA
chr11	532242	535576	minus	Core	No	No	Yes	No	HRAS	except, Exon, 5	3A	None	NA	NA	NA	NA	NA	NA	NA	Mutations in HRAS are extremely rare in myeloid leukemia (PMID: 19075190)	NA
chr2	208236228	208255071	minus	Core	No	Yes	Yes	No	IDH1	GOF	1 or 2 depending on disease context	Ivosidenib	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	IDH1 mutations are identified in 6-9% of AML cases, <5% of MDS and MPN cases. For AML, treatment with the IDH1 inhibitor ivosidenib may be of benefit (NCCN Guidelines - AML 2023). For MDS, there is emerging data demonstrating the effectiveness of ivosidenib for MDS (Medeiros (2017) PMID:27721426; NCCN Guidelines - MDS 2022). For MPN cases, IDH1 mutations in PV and ET are associated with inferior overall survival and in PMF with inferior leukemia-free survival and leukemic transformation (NCCN Guidelines - MPN 2022).	NA
chr15	90083044	90102468	minus	Core	No	Yes	Yes	No	IDH2	GOF	1A for MDS ior MPN, 3A for AML	Enasidenib	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	IDH2 mutations are identified in 10-20% of AML cases, <5% of MDS cases, and <5% of MPN cases. The IDH2 inhibitor enasidenib has been withdrawn from Health Canada for relapsed/refractory AML as of 30 June 2023 following Phase 3 clinical trials (https://recalls-rappels.canada.ca/en/alert-recall/idhifa-enasidenib-mesylate-market-withdrawal-and-continued-access; NCCN Guidelines - AML 2023). IDH2 mutations have been associated with inferior outcomes. This notwithstanding, there is emerging data demonstrating the effectiveness of enasidenib in IDH2 mutated MDS (NCCN Guidelines - MDS v1.2023). IDH2 mutations in PV and ET are associated with inferior overall survival and in PMF with inferior leukemia-free survival and leukemic transformation (NCCN Guidelines - MPN 2022).	NA
chr7	50304715	50405101	plus	Expanded	No	Yes	Yes	Yes	IKZF1	LOFminush	3A	None	NA	NA	NA	NA	NA	NA	NA	IKZF1 mutation is one rare but recurrent alteration in AML but the clinical impact of IKZF1 mutation on AML remains undefined (PMID: 33081843).	NA
chr5	132481608	132490773	minus	No	No	Yes	No	No	IRF1	LOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr1	64833228	65067746	minus	No	No	Yes	No	No	JAK1	GOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr9	4984390	5129948	plus	Core	Yes	Yes	Yes	No	JAK2	GOF, FUS	1A	None	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, (WHO, PMID: 35732831).	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions; myeloid/lymphoid neoplasm with JAK2 rearrangement, (ICC, PMID: 35767897).	t(8;9)(p22;p24.1)/ PCM1::JAK2	ETV6, BCR, PCM1	Common: MPN or MDS/MPNlike BM with eosinophilia	Limited responses to ruxolitinib	NA	Optical Genome Mapping detected a translocation t(9;12)(p24;p13), t(9;22)(p24;q11.2), or t(8;9)(p22;p24.1) with the JAK2 gene (9p24.1) with a variant allele frequency of ___. The ETV6::JAK2, BCR::JAK2, or PCM1::JAK2 fusion is a rare, but recurrent rearrangement seen in myeloid and lymphoid neoplasia with eosinophilia and may respond to targeted therapy (limited response to ruxolitib). The BCR fusion is oncogenic, PCM1 is likely oncogenic and ETV6 is unknown.	NA
chr19	17824781	17847982	minus	No	No	Yes	Yes	No	JAK3	GOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr9	504694	746103	plus	No	No	Yes	No	No	KANK1	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr8	41929478	42051987	minus	No	No	Yes	No	No	KAT6A	FUS	1A if fused to CREBBP, otherwise 3A	None	NA	NA	NA	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(8;16)(p11.2;p13.3) with a variant allele frequency (VAF) of [%]. The t(8;16)(p11.2;p13.3) is a rare, recurrent abnormality resulting in a KAT6A::CREBBP fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). KAT6A::CREBBP associated with adverse risk category (ELN, PMID: 35797463).	NA
chrX	44873188	45112779	plus	Core	No	No	Yes	Yes	KDM6A	NA	3A	None	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	KDM6A mutations are identified in approximately 2% of AML cases (COSMIC), 1-2% of MDS cases and is rarely identified in MPN. The predictive and prognostic significance of KDM6A mutations in AML, MDS and MPN remain uncertain.	NA
chr10	32009014	32056425	minus	No	No	Yes	No	No	KIF5B	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr4	54657956	54740715	plus	Core	No	Yes	Yes	No	KIT	GOF	2 for AML, 3A for MDS and MPN	Avapritinib	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	KIT mutations are identified in ~20% of CBF-AML (DiNardo (2016) PMID:27913501) and are infrequent in MDS and MPN. A meta-analysis of CBF AML showed that a KIT mutation in patients with t(8;21), but not inv(16), was associated with an increased risk of relapse and shorter OS (Chen (2016) PMID: 26771376). Nevertheless, 2017 ELN guidelines indicate that KIT mutation status should not be used to assign a patient to a different genetic risk category (Dohner (2017) PMID: 27895058). The predictive and prognostic significance of KIT mutations in MDS and MPN remains uncertain	NA
chr11	118436456	118526832	plus	Core	Yes	Yes	No	Yes	KMT2A	GOF, FUS	1A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with KMT2A rearrangement, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A = 10%. Classification of AML with percentage of blasts required for diagnosis; AML with other KMT2A rearrangements† = 10%, (ICC, PMID: 35767897).	AFF1, AFDN, MLLT3, MLLT10, TET1, ELL, MLLT1	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Optical Genome Mapping detected a t(v;11q23.3)/KMT2A-rearrangement associated with _____ risk category in the context of AML based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. Over 100 KMT2A fusion partners have been described where the seven most frequent translocation partners account for more than 90% of all recombinations of the KMT2A, 37 occur recurrently and 63 were identified so far only once (PMID: 37019990). AFF1, AFDN, MLLT10, TET1, ELL and MLLT1 fusion partners are associated with adverse risk categorization whereas MLLT3 is associacted with intermediate risk (ELN, PMID: 35797463). The presence of t(9;11)(p21.3;q23.3) MLLT3::KMT2A takes precedence over rare, concurrent adverse risk gene mutations. t(v;11q23.3)/KMT2A-rearrangement is associated with adverse risk category excluding KMT2A partial tandem duplication (PTD)(ELN, PMID: 35797463).	NA
chr12	25205245	25250929	minus	Core	No	Yes	Yes	No	KRAS	GOF	1B for MDS and MPN, 3A for AML	Adagrasib	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	RAS mutations are identified in ~6% of AML patients (Metzeler (2016) PMID:27288520), 1-2% of MDS patients with a higher frequency in JMML patients (10-15%) (NCCN Guidelines - MDS 2023), and 6% of MPN cases. KRAS mutations have not been found to be a significant prognostic marker in AML but are associated with poor outcome in MDS and MPN (PMID:30194935, PMID:21220588, PMID:28223278, PMID:31628430).	NA
chr3	169083499	169663775	minus	Expanded	Yes	Yes	No	No	MECOM	FUS	1A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with MECOM rearrangement, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2; MECOM(EVI1) = 10%. Classification of AML with percentage of blasts required for diagnosis; AML with other MECOM rearrangements‡ = 10%, (ICC, PMID: 35767897).	GATA2, MYC, ETV6, RUNX1	NA	NA	NA	AML	Optical Genome Mapping detected a t(3;8)(q26.2;q24.2), t(3;12)(q26.2;p13.2), t(3;21)(q26.2;q22.1), inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2). This is a recurrent abnormality resulting in a GATA2::MECOM(EVI1), MYC::MECOM, ETV6::MECOM, RUNX1::MECOM or novel t(3q26.2;v)/MECOM(EVI1)-rearrangement associated with adverse risk category (ELN, PMID: 35797463)	NA
chr1	156463727	156500779	minus	No	Yes	Yes	No	No	MEF2D	Gene rearrangement	1A	None	Classification of B-ALL , (WHO, PMID: 35732831).	B-ALL with MEF2D rearrangement, (ICC, PMID: 35767897).	BCL9, HNRNPUL1	NA	NA	NA	NA	Poor	NA
chr3	158571193	158606456	plus	No	No	Yes	No	No	MLF1	FUS	1A if fused to NPM1, otherwise 3A	None	NA	NA	NA	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(3;5)(q25.3;q35.1) with a variant allele frequency (VAF) of [%]. This is a rare, recurrent abnormality resulting in a NPM1::MLF1 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (ICC, PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.	NA
chr19	6210380	6279975	minus	No	No	Yes	No	No	MLLT1	FUS	1A if fused to KMT2A, otherwise 3A	None	NA	NA	KMT2A	NA	NA	NA	AML	Optical Genome Mapping detected a translocation t(11;19)(q23.3;p13.3) with a variant allele frequency (VAF) of [%]. The t(11;19)(q23.3;p13.3) is a recurrent abnormality resulting in a MLLT1::KMT2A fusion. In the context of AML it is considered to have a adverse favorable prognosis according to the ELN 2022 (PMID: 35797463).	NA
chr10	21534231	21743630	plus	No	No	Yes	No	Yes	MLLT10	FUS	1A if fused to KMT2A or PICALM, otherwise 3A	None	NA	NA	KMT2A, PICALM	NA	NA	NA	AML	Optical Genome Mapping detected a translocation t(10;11)(p12.3;q23.3) or t(10;11)(p12.3;q14.2) with a variant allele frequency (VAF) of [%]. The t(10;11)(p12.3;q23.3) is a recurrent abnormality resulting in a MLLT10::KMT2A fusion. The t(10;11)(p12.3;q14.2) is a rare, recurrent abnormality resulting in a PICALM::MLLT10 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). In the context of AML, MLLT10::KMT2A fusion is considered to have a adverse favorable prognosis according to the ELN 2022, the PICALM::MLLT10 fusion has an unclear prognosis due to its rarity (PMID: 35797463).	NA
chr9	20341669	20622499	minus	No	Yes	Yes	No	No	MLLT3	Gene fusion	1A if fused to KMT2A, otherwise 3A	None	NA	Classification of AML with percentage of blasts required for diagnosis; AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A = 10%, (ICC, PMID: 35767897).	KMT2A	NA	NA	NA	AML	Optical Genome Mapping detected a t(9;11)(p21.3;q23.3)/MLLT3::KMT2A associated with interemediate risk category in the context of AML based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverserisk gene mutations. (ELN, PMID: 35797463)	NA
chr1	43337817	43354466	plus	Core	No	Yes	Yes	No	MPL	GOFminush	1A for MPN, 3A for MDS and AML	None	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	MPL activating mutations are rarely identified in AML cases. The predictive and prognostic significance of MPL mutations in AML remain uncertain. MPL mutations are identified in <5% of MDS patients and are often identified in combination with SF3B1 in MDS/MPN with ring sideroblasts and thrombocytosis (NCCN Guidelines - MDS 2023). Activating MPL mutations are identified in 5-8% of PMF patients and 1-4% of ET patients and are a major diagnostic criterion for these diseases (NCCN Guidelines - MPN 2023).	NA
chr22	40410281	40636719	minus	No	Yes	Yes	No	No	MRTFA	Gene fusion	1A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with RBM15::MRTFA fusion, (WHO, PMID: 35732831).	NA	NA	NA	NA	NA	NA	NA	NA
chr6	135181307	135219172	plus	No	No	Yes	No	No	MYB	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr8	127735434	127742951	plus	No	Yes	Yes	No	No	MYC	Mutated gene	1A	None	NA	Classification of B-ALL ;B-ALL with MYC rearrangement, (ICC, PMID: 35767897).	IGH, MECOM	NA	NA	NA	NA	Optical Genome Mapping detected a t(3;8)(q26.2;q24.2). This is a recurrent abnormality resulting in a MYC::MECOM fusion associated with adverse risk category in AML (ELN, PMID: 35797463)	NA
chr3	38138660	38143022	plus	No	No	Yes	Yes	No	MYD88	GOFminush	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr16	15703135	15857028	minus	No	Yes	Yes	No	No	MYH11	Gene fusion	1A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with CBFB::MYH11 fusion, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11 = 10%, (ICC, PMID: 35767897).	NA	NA	NA	NA	AML	Optical Genome Mapping detected a translocation inv(16)(p13.1q22) or t(16;16)(p13.1;q22) which is a recurrent abnormality resulting in a CBFB::MYH11 fusion. In the context of AML it is considered to have a favourable favorable prognosis mainly based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. Concurrent KIT and/or FLT3 gene mutation does not alter risk categorization (ELN, PMID: 35797463)	NA
chr1	58654744	58700062	minus	Expanded	No	No	No	No	MYSM1	Exon, 16	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr17	31094926	31377677	plus	Expanded	No	Yes	No	Yes	NF1	LOF	3A	Selumetinib	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	NF1 mutations are identified in ~5% of AML cases. The predictive and prognostic significance of NF1 mutations in AML remain uncertain. NF1 mutations are identified in ~5% of MDS cases. The predictive and prognostic significance of NF1 mutations in MDS remain uncertain. NF1 mutations are identified in ~5% of MPN cases. The predictive and prognostic significance of NF1 mutations in MPN remain uncertain.	NA
chr12	54292110	54295758	minus	No	No	Yes	No	No	NFE2	GOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr14	50719762	50831162	minus	No	No	Yes	No	No	NIN	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr9	136494432	136546048	minus	No	No	Yes	Yes	No	NOTCH1	LOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr5	171387116	171411810	plus	Core	Yes	Yes	Yes	No	NPM1	Mutated gene	1A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with NPM1 mutation, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with mutated NPM1 = 10%, (ICC, PMID: 35767897).	RARA, TYK2, MLF1	NA	NA	NA	AML	Optical Genome Mapping detected a translocation t(5;17)(q35.1;q21.2), t(5;19)(q35;p13) or t(3;5)(q25.3;q35.1) with a variant allele frequency (VAF) of [%]. This is a rare, recurrent abnormality resulting in a NPM1::RARA, NPM1::TYK2 or NPM1::MLF1 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (ICC, PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear. Mutated NPM1 without FLT3-ITD has favourable risk category based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. Mutated NPM1 with FLT3-ITD associated with intermediate risk category based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. AML with NPM1 mutation and adverse-risk cytogenetic abnormalities are categorized as adverse-risk. (ELN, PMID: 35797463)	NA
chr1	114704468	114716771	minus	Core	No	Yes	Yes	No	NRAS	GOF	1B for MDS and MPN, 3A for adult AML	Panitumumab, Panitumumab + Chemotherapy	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	NRAS mutations have been identified in 13-14% of AML patients. In adult AML, NRAS mutations have not been found to be a significant prognostic marker, however, they have been associated with an adverse prognosis in pediatric AML (Liu (2018) PMID:30194935). RAS mutations have been identified in 5-10% of MDS patients, with a higher frequency in CMML and JMML patients (~15%). In MDS, RAS mutations are associated with an inferior outcome (NCCN Guidelines - MDS 2023). . NRAS mutations have been identified in 6% of MPN cases. In MF, RAS mutations have been associated with inferior outcomes (Santos (2020) PMID: 31628430).	NA
chr5	177133772	177300213	plus	No	No	Yes	No	No	NSD1	FUS	1A if fused to NUP98, otherwise 3A	None	NA	NA	NUP98	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(5;11)(q35.2;p15.4) with a variant allele frequency (VAF) of [%]. The t(5;11)(q35.2;p15.4) is a rare, recurrent abnormality resulting in a NUP98::NSD1 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.	NA
chr15	87859750	88256739	minus	No	No	Yes	No	No	NTRK3	FUS	2	Larotrectinib	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr9	131125573	131234663	plus	No	Yes	Yes	No	No	NUP214	Gene fusion	1A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with DEK::NUP214 fusion, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with t(6;9)(p22.3;q34.1)/DEK::NUP214 = 10%, (ICC, PMID: 35767897).	NA	NA	NA	NA	AML	Optical Genome Mapping detected a translocation t(6;9)(p22.3;q34.1) with a variant allele frequency (VAF) of [%]. The t(6;9)(p22.3;q34.1) is a recurrent abnormality resulting in a DEK::NUP214 fusion. In the context of AML it is considered to have a adverse prognosis according to the ELN 2022 (PMID: 35797463).	NA
chr11	3671083	3797792	minus	No	Yes	No	No	No	NUP98	Gene rearrangement	1A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with NUP98 rearrangement, (WHO, PMID: 35732831).	NA	NSD1, KMD5A	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(11;12)(p15.4;p13.3), t(5;11)(q35.2;p15.4), or t(11;v)(p15.4;v) with a variant allele frequency (VAF) of [%]. This is a rare, recurrent abnormality resulting in a NUP98::KMD5A or NUP98::NSD1 or NUP98::v fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.	NA
chr15	34343315	34357737	plus	No	Yes	Yes	No	No	NUTM1	Gene rearrangement	2	None	NA	Classification of B-ALL; B-ALL with NUTM1 rearrangement, (ICC, PMID: 35767897).	ACIN1, ZNF618, BRD9, IKZF1, CUX1	NA	NA	NA	NA	Good	NA
chrX	1462580	1537185	minus	No	No	Yes	No	No	P2RY8_chrX	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chrY	1462580	1537185	minus	No	No	Yes	No	No	P2RY8_chrY	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr9	36833269	37034268	minus	Expanded	Yes	Yes	No	No	PAX5	Mutated gene	1A	None	NA	Acute lymphoblastic leukemia with germline predisposition* ; Acute lymphoblastic leukemia with germline PAX5 mutation, (ICC, PMID: 35767897).	NA	NA	NA	NA	NA	NA	NA
chr1	164555584	164899296	plus	No	Yes	Yes	No	No	PBX1	Gene fusion	1A if fused with TCF3, otherwise 3A	None	NA	B-ALL with t(1;19)(q23.3;p13.3)/TCF3::PBX1, (ICC, PMID: 35767897).	NA	NA	NA	NA	NA	NA	NA
chr8	17922987	18029948	plus	No	No	Yes	No	No	PCM1	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr1	148844427	149033016	plus	No	No	Yes	No	No	PDE4DIP	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr4	54229280	54298245	plus	No	Yes	Yes	Yes	Yes	PDGFRA	Gene rearrangement	1A	Imatinib	NA	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusion; Myeloid/lymphoid neoplasm with PDGFRA rearrangement, (ICC, PMID: 35767897).	Cryptic deletion at 4q12/ FIP1L1::PDGFRA	CDK5RAP2; STRN; KIF5B; TNKS2; ETV6, BCR	Common: CEL-like BM with frequent extramedullary involvement	Excellent response to TKI	NA	Optical Genome Mapping detected a translocation or deletion of the PDGFRA gene (4q12) with the CDK5RAP2, STRN, FIP1L1, KIF5B, TNKS2, ETV6, or BCR gene with a variant allele frequency of ___. The CDK5RAP2::PDGFRA, STRN::PDGFRA, FIP1L1::PDGFRA, KIF5B::PDGFRA, TNKS2::PDGFRA, ETV6::PDGFRA, or BCR::PDGFRA fusion is a recurrent rearrangement seen in myeloid and lymphoid neoplasia with eosinophilia and will likely respond well to tyrosine kinase inhibitors. This fusion is likely oncogenic (except for TNKS2::PDGFRA) and has a likely gain of function mutation effect (PMID: 35767897).	NA
chr5	150113839	150155872	minus	No	Yes	Yes	No	No	PDGFRB	Gene rearrangement	1A	Imatinib	NA	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions; Myeloid/lymphoid neoplasm with PDGFRB rearrangement, (ICC, PMID: 35767897).	t(5;12)(q32;p13.2)/ ETV6::PDGFRB	>30 partners (ETV6, PDE4DIP, TPM3, SPTBN1, GOLGA4, WDR48, GOLGB1, PRKG2, CD74, TNIP1, HECW1, HIP1, KANK1, CCDC6, CAPRIN1, ERC1, BIN2, SART3, GIT2, NIN, CCDC88C, TRIP11, TP53BP1, NDE1, RABEP1, MPRIP, SPECC1, MYO18A, COL1A1, DTD1, ZMYND8)	Common: CEL-like or monocytosis with eosinophilia	Excellent response to TKI	NA	Optical Genome Mapping detected a _______ translocation resulting in a ______::PDGFRB fusion gene with a variant allele frequency of []. The ____::PDGFRB fusion is a recurrent rearrangement seen in myeloid and lymphoid neoplasia with eosinophilia and will likely respond well to tyrosine kinase inhibitors (PMID: 35767897).	NA
chrX	134373311	134428790	plus	Core	No	Yes	Yes	Yes	PHF6	LOF	3A	None	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	PHF6 loss-of-function mutations are identified in approximately 3% of AML cases (Todd (2015) PMID:26103525) but are reported to be more frequent in mixed phenotype acute leukemias (Xiao (2018) PMID:30530780). The predictive and prognostic significance of PHF6 mutations in AML remain uncertain (Mori (2016) PMID:27479181). PHF6 loss-of-function mutations are identified in less than 5% of MDS cases. In MDS, PHF6 mutations are more frequent in cases with excess blasts but are not reported to be independently prognostic (NCCN Guidelines - MDS 2023). PHF6 loss-of-function mutations are identified in approximately 1% of MPN cases. The predictive and prognostic significance of PHF6 mutations in MPN remain uncertain (Mori (2016) PMID:27479181).	NA
chr11	85957174	86069084	minus	No	No	Yes	No	No	PICALM	FUS	1A if fused with MLLT10, otherwise 3A	None	NA	NA	MLLT10	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(10;11)(p12.3;q14.2) with a variant allele frequency (VAF) of [%]. The t(10;11)(p12.3;q14.2) is a rare, recurrent abnormality resulting in a PICALM::MLLT10 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.	NA
chrX	15319451	15335554	minus	Core	No	No	No	No	PIGA	NA	2	None	NA	NA	NA	NA	NA	NA	MDS	Pathogenic variants in PIGA alter GPI anchor biosynthesis and are associated with paroxysmal nocturnal hemoglobinura (PNH) (Lee (2014) PMID:25244089; Mortazavi (2000) PMID:10627475; Araten (1999) PMID:10220445; Takeda (1993) PMID:8500164).	NA
chr15	73994673	74047827	plus	No	Yes	Yes	No	No	PML	Gene fusion GOF	1A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute promyelocytic leukaemia with PML::RARA fusion, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; Acute promyelocytic leukemia (APL) with t(15;17)(q24.1;q21.2)/PML::RARA = 10%, (ICC, PMID: 35767897).	NA	NA	NA	NA	APL	Optical Genome Mapping detected a translocation t(15;17)(q24;q21) with a variant allele frequency (VAF) of [%]. The t(15;17) is a recurrent abnormality fusing the PML and RARA genes (canonical fusion). In the context of AML it is considered to have a favorable prognosis according to the ELN 2022. (PMID: 35797463).

	NA
chr17	60600192	60666280	plus	Expanded	No	Yes	No	No	PPM1D	LOF	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr1	3069202	3438621	plus	No	No	Yes	No	No	PRDM16	FUS	1A if fused with RPN1, otherwise, 3A	None	NA	NA	NA	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(1;3)(p36.3;q21.3) with a variant allele frequency (VAF) of [%]. The t(1;3)(p36.3;q21.3) is a rare, recurrent abnormality resulting in a PRDM16::RPN1 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.	NA
chr4	81087374	81215222	minus	No	No	Yes	No	No	PRKG2	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr12	49623414	49644669	plus	Core	No	No	No	No	PRPF40B	NA	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr17	1650628	1684867	minus	No	No	Yes	No	No	PRPF8	LOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr10	87863625	87971930	plus	Core	No	No	Yes	No	PTEN	&, Promoter	3A	None	NA	NA	NA	NA	NA	NA	AML	PTEN mutations are rare in AML cases. The predictive and prognostic significance of PTEN mutations in AML remain uncertain.	NA
chr12	112418946	112509918	plus	Core	No	Yes	Yes	No	PTPN11	GOF	1B for MDS and AML, 3A for MPN	None	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	PTPN11 mutations are identified in ~5% of AML cases (Hou (2008) PMID: 1797295). In AML, PTPN11 mutations have been associated with a poor prognosis (Alfayez (2020) PMID: 32561839). Although PTPN11 mutations are rare in adult MDS, they are identified in ~10% of pediatric MDS and in ~34% of non-syndromic JMML (Tartaglia (2003) PMID: 12717436). PTPN11 mutation have been correlated with poorer overall survival, however, PTPN11 status should not be used to determine the effectiveness of hypomethylating agents (NCCN Guidelines - MDS 2022). Although PTPN11 mutations are rare in MPN, they are identified in ~34% of non-syndromic JMML (Tartaglia (2003) PMID: 12717436). The predictive and prognostic significance of PTPN11 mutations in MPN remain uncertain.	NA
chr17	5282283	5386340	plus	No	No	Yes	No	No	RABEP1	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr8	116845933	116874776	minus	Core	No	Yes	Yes	Yes	RAD21	LOF	3A	None	NA	NA	NA	NA	NA	NA	AML and MDS	AD21 mutations are identified in approximately 4-5% of AML cases. The predictive and prognostic significance of RAD21 mutations in AML remain uncertain (Tsai (2017) PMID:29288251; Thol (2014) PMID:24335498). Mutations in cohesin complex genes, including RAD21, are identified in approximately 8-12% of MDS cases (Kon (2013) PMID:23955599; Thota (2014) PMID:25006131). Although one study identified an association between cohesin complex mutations and a decreased overall survival (Thota (2014) PMID:25006131) there is insufficient data on the prognosis and predictive significance of cohesion complex gene mutation in MDS.	NA
chr17	40309180	40357643	plus	No	Yes	Yes	No	No	RARA	Gene fusion GOF	1A	Arsenic Trioxide	Acute myeloid leukaemia with defining genetic abnormalities; Acute promyelocytic leukaemia with PML::RARA fusion, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; Acute promyelocytic leukemia (APL) with t(15;17)(q24.1;q21.2)/PML::RARA = 10%; APL with other RARA rearrangements* = 10%, (ICC, PMID: 35767897).	PML, BCOR, FIP1L1, TBL1XRA, STAT3, STAT5B, ZBTB16, NPM1, IRF2BP2	NA	NA	NA	APL, AML	Optical Genome Mapping detected a translocation t(15;17)(q24;q21) or t(5;17)(q35.1;q21.2) with a variant allele frequency (VAF) of [%]. The t(15;17) is a recurrent abnormality fusing the PML and RARA genes (canonical fusion) or forming a NPM1::RARA fusion. In the context of AML, PML::RARA is considered to have a favorable prognosis and NPM1::RARA prognosis is unclear according to the ELN 2022. The NPM1::RARA, ZBTB16::RARA, STAT5B::RARA, STAT3::RARA, TBL1XR1::RARA, FIP1L1::RARA, BCOR::RARA fusions are rare, atypical, but recurrent variant RARA translocations (PMID: 35797463).

	NA
chr13	48303750	48481890	plus	No	No	Yes	No	Yes	RB1	LOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr1	110338506	110346681	plus	No	Yes	Yes	No	No	RBM15	Gene fusion	1A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with RBM15::MRTFA fusion, (WHO, PMID: 35732831).	NA	MRTF1	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(1;22)(p13.3;q13.1) with a variant allele frequency (VAF) of [%]. The t(1;22)(p13.3;q13.1) is a rare, recurrent abnormality resulting in a RBM15::MRTF1 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.	NA
chr1	155897808	155911349	minus	Expanded	No	No	No	No	RIT1	Exons, 2,, 4-5	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr1	23691806	23696835	plus	Expanded	No	No	No	No	RPL11	Exon, 3	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr3	128619968	128650818	minus	No	No	Yes	No	No	RPN1	FUS	1A if fused with PRDM16, otherwise 3A	None	NA	NA	NA	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(1;3)(p36.3;q21.3) with a variant allele frequency (VAF) of [%]. The t(1;3)(p36.3;q21.3) is a rare, recurrent abnormality resulting in a PRDM16::RPN1 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.	NA
chr20	63657810	63696253	plus	Expanded	No	No	No	Yes	RTEL1	NA	1B	None	NA	NA	NA	NA	NA	NA	MDS	Heterozygous RTEL variants have been associated with aplastic anemia, unexplained cytopenias and hypoplastic MDS (Marsh (2018) PMID:29344583). As a hereditary change, loss-of-function mutations in RTEL are associated with short telomere syndromes (NCCN Guideline - MDS 2023). A referral to the BCCA Hereditary Cancer Program may be warranted (http://www.screeningbc.ca/Hereditary/). This missense variant in RTEL has not been biochemically characterized in the literature but has been associated with a short telomere syndrome (REF). Heterozygous RTEL variants have been associated with aplastic anemia, unexplained cytopenias and hypoplastic MDS (Marsh (2018) PMID:29344583). As a hereditary change, loss-of-function mutations in RTEL are associated with short telomere syndromes (NCCN Guideline - MDS 2023). A referral to the BCCA Hereditary Cancer Program may be warranted (http://www.screeningbc.ca/Hereditary/).	NA
chr21	34787801	36004667	minus	Core	Yes	Yes	Yes	Yes	RUNX1	GOF	1A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 = 10%; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897).	RUNXT1. MECOM	CBFA2T3	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Optical Genome Mapping detected a translocation t(8;21)(q22;q22.1) or t(3;21)(q26.2;q22.1) or t(16;21)(q24.3;q22.1) with a variant allele frequency (VAF) of [%]. t(8;21)(q22;q22.1) or t(3;21)(q26.2;q22.1) are recurrent abnormality resulting in a RUNX1::RUNX1T1 or RUNX1::MECOM fusion. In the context of AML it is considered to have a favourable prognosis for RUNX1::RUNXT1 fusion and adverse prognosis for RUNX1::MECOM fusion, mainly based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. The t(16;21)(q24.3;q22.1) is a rare, recurrent abnormality resulting in a RUNX1::CBFA2T3 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity with an unclear prognosis (PMID: 35767897). Concurrent KIT and/or FLT3 gene mutation does not alter risk categorization. Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463).	NA
chr8	91954967	92103286	minus	No	Yes	Yes	No	No	RUNX1T1	GOF	1A	None	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 = 10%; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897).	NA	NA	NA	NA	AML	Optical Genome Mapping detected a translocation t(8;21)(q22;q22.1) with a variant allele frequency (VAF) of [%]. The t(8;21)(q22;q22.1) is a recurrent abnormality resulting in a RUNX1::RUNX1T1 fusion. In the context of AML it is considered to have a favourable favorable prognosis mainly based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. Concurrent KIT and/or FLT3 gene mutation does not alter risk categorization. Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)	NA
chr7	93099513	93118023	minus	Expanded	Yes	No	No	No	SAMD9	Mutated gene	1A	None	NA	Hematologic neoplasms with germline predisposition associated with a constitutional disorder affecting multiple organ systems; Myeloid neoplasms with germline SAMD9 mutation, (ICC, PMID: 35767897).	NA	NA	NA	NA	NA	NA	NA
chr7	93130056	93148385	minus	No	Yes	No	No	No	SAMD9L	Mutated gene	1A	None	NA	Hematologic neoplasms with germline predisposition associated with a constitutional disorder affecting multiple organ systems; Myeloid neoplasms with germline SAMD9L mutation, (ICC, PMID: 35767897).	NA	NA	NA	NA	NA	NA	NA
chr7	66987680	66995586	minus	Expanded	No	No	No	No	SBDS	NA	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr18	44680887	45068510	plus	Expanded	No	Yes	Yes	No	SETBP1	GOF	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr3	47016408	47164113	minus	Core	No	No	No	Yes	SETD2	NA	3A	None	NA	NA	NA	NA	NA	NA	AML, MDS	SETD2 mutations are identified in approximately 6% of AML cases. The predictive and prognostic significance of SETD2 mutations in AML remain uncertain. SETD2 mutations are rarely identified in MDS cases. The predictive and prognostic significance of SETD2 mutations in MDS remain uncertain.	NA
chr11	64764604	64778844	minus	Core	No	No	No	Yes	SF1	NA	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr22	30331988	30356894	minus	Core	No	No	No	No	SF3A1	NA	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr2	197388515	197435079	minus	Core	Yes	Yes	Yes	No	SF3B1	Mutated gene	1A	None	Classification and defining features of myelodysplastic neoplasms (MDS); MDS with low blasts and SF3B1 mutationa (MDS-SF3B1). Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2. Premalignant clonal cytopenias and myelodysplastic syndromes; Myelodysplastic syndrome with mutated SF3B1, (ICC, PMID: 35767897).	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)	Absence of 5q deletion, monosomy 7, or complex karyotype
chr12	111405922	111451623	plus	Core	No	Yes	No	No	SH2B3	LOF	1B for MPN, 3A for MDS, AML	None	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	SH2B3 mutations are associated with inferior overall survival, for MF-free survival, and in patients with ET (NCCN Guidelines - MPN 2022). Mutations in SH2B3 have been identified in <1% of MDS patients. The predictive and prognostic significance of SH2B3 in MDS remain uncertain. Mutations in SH2B3 are rarely identified in AML patients. The predictive and prognostic significance of SH2B3 in AML remain uncertain.	NA
chrX	53374149	53422728	minus	Core	No	No	Yes	No	SMC1A	NA	3A	None	NA	NA	NA	NA	NA	NA	AML	SMC1A mutations have been found in ~2% of AML patients (Metzeler (2016) PMID:27288520 ). Cohesin complex gene mutations have no clear prognostic impact in AML patients (Yi (2017) PMID:28924389; Thol (2014) PMID:24335498).	NA
chr10	110567691	110604634	plus	Core	No	No	Yes	No	SMC3	NA	3A	None	NA	NA	NA	NA	NA	NA	AML, MDS	SMC3 mutations are rare in AML cases. The predictive and prognostic significance of SMC3 mutations in AML remain uncertain but may depend on the presence of other cooperating mutations (Cuartero (2019) PMID: 31552185; Mazumdar (2017) PMID: 27796738). MC3 mutations are rare in MDS cases. The predictive and prognostic significance of SMC3 mutations in MDS remain uncertain and may depend on the presence of other cooperating mutations (Fisher (2017) PMID: 28626802).	NA
chr17	78356777	78360079	minus	Core	No	No	No	No	SOCS3	Exon, 2	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr2	54456326	54671446	plus	No	No	Yes	No	No	SPTBN1	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr4	56467617	56503681	plus	Expanded	No	No	No	No	SRP72	NA	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr17	76734115	76737333	minus	Core	Yes	Yes	Yes	Yes	SRSF2	Mutated gene	1A	None	Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897).	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)	NA
chrX	123960212	124422664	plus	Core	Yes	Yes	Yes	Yes	STAG2	Mutated gene	1A	None	Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897).	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)	NA
chr17	42313323	42388442	minus	No	No	Yes	No	No	STAT3	GOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr17	42287546	42311943	plus	No	No	Yes	No	No	STAT5a	GOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr17	42199176	42276391	minus	No	No	Yes	No	No	STAT5b	GOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr1	47250138	47314147	minus	No	No	Yes	No	No	STIL	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr11	3855664	4093208	plus	Expanded	No	No	No	No	STIM1	Exon, 7	3A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr2	36837697	36966536	minus	No	No	Yes	No	No	STRN	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr1	47216290	47232225	minus	No	No	Yes	No	No	TAL1	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr19	1609291	1652615	minus	No	Yes	Yes	No	No	TCF3	Gene fusion	1A if fused with PBX1, otherwise 3A	None	NA	Classification of B-ALL; B-ALL with t(1;19)(q23.3;p13.3)/TCF3::PBX1, (ICC, PMID: 35767897).	NA	NA	NA	NA	NA	NA	NA
chr3	169764609	169765060	minus	Expanded	No	Yes	No	Yes	TERC	LOFminush	1A	None	NA	NA	NA	NA	NA	NA	Myeloid	TERC variants are rarely identified as a somatic change in myeloid malignancies. As a germline change, TERC mutations are the cause autosomal dominant dyskeratosis congenita (Savage (2009) PMID:20301779). A referral to the BCCA Hereditary Cancer Program may be warranted (http://www.screeningbc.ca/Hereditary/).	NA
chr5	1253166	1295068	minus	Expanded	No	Yes	No	Yes	TERT	LOFminush	1A for MDS, 3A for AML	None	NA	NA	NA	NA	NA	NA	MDS	Somatic TERT variants are identified in ~1% of myeloid malignancies and are the cause autosomal dominant dyskeratosis congenita when identified in the germline (Basel-Vanagaite (2008) PMID:18460650). A referral to the BCCA Hereditary Cancer Program may be warranted (http://www.screeningbc.ca/Hereditary/).	NA
chr10	68560336	68694487	plus	No	No	Yes	No	Yes	TET1	FUS	1A if fused with KMT2A, otherwise 3A	None	NA	NA	NA	NA	NA	NA	AML	Optical Genome Mapping detected a translocation t(10;11)(q21.3;q23.3) with a variant allele frequency (VAF) of [%]. The t(10;11)(q21.3;q23.3) is a recurrent abnormality resulting in a TET1::KMT2A fusion. In the context of AML it is considered to have a adverse favorable prognosis according to the ELN 2022 (PMID: 35797463).	NA
chr4	105146875	105279803	plus	Core	No	Yes	Yes	Yes	TET2	LOF	2	None	NA	NA	NA	NA	NA	NA	NA	TET2 mutations have been identified in approximately 10-20% of AML cases. In AML, a recent meta-analysis revealed TET2 mutations to be associated with inferior outcomes (Wang (2019) PMID:31023266). While TET2 mutations have been identified in approximately 20-25% of MDS cases, they have not been found to be a significant prognostic marker. Response to hypomethylating agents does however appear to be better in patients harbouring TET2 mutations (NCCN Guidelines - MDS 2023).	NA
chr17	7661779	7687538	minus	Core	Yes	Yes	Yes	Yes	TP53	Mutated gene	1A	None	Classification and defining features of myelodysplastic neoplasms (MDS).; MDS with biallelic TP53 inactivation (MDS-biTP53). Subtypes of myeloid neoplasms associated with germline predisposition; Myeloid neoplasms with germline predisposition without a pre-existing platelet disorder or organ dysfunction, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML and MDS/AML with mutated TP53† 10-19% (MDS/AML) and = 20% (AML). Hematologic neoplasms with germline predisposition without a constitutional disorder affecting multiple organ systems; Myeloid or lymphoid neoplasms with germline TP53 mutation. Premalignant clonal cytopenias and myelodysplastic syndromes; Myelodysplastic syndrome with mutated TP53. Premalignant clonal cytopenias and myelodysplastic syndromes; MDS/AML with mutated TP53, (ICC, PMID: 35767897).	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Optical Genome Mapping detected a [INSERT REARRANGEMENT TYPE] on chromosome 17 involving the TP53 gene with a variant allele frequency of []. Loss of function structural variants in TP53 likely have an adverse prognosis (PMID: 28179279,27069254, 35797463)	Usually complex
chr15	43403060	43493156	minus	No	No	Yes	No	No	TP53BP1	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr19	10350532	10380572	minus	No	No	Yes	No	No	TYK2	GOF	1A if fused with NPM1, otherwise 3A	None	NA	NA	NPM1	NA	NA	NA	NA	Optical Genome Mapping detected a translocation t(5;19)(q35;p13) with a variant allele frequency (VAF) of [%]. This is a rare, recurrent abnormality resulting in a NPM1::TYK2 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (ICC, PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.	NA
chr21	43092956	43107570	minus	Core	Yes	Yes	Yes	No	U2AF1	Mutated gene	1A	None	Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897).	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)	NA
chr19	55654050	55674716	plus	Core	No	No	No	No	U2AF2	NA	1B	None	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	U2AF1 variants have been identified in ~4% of AML patients (cBioPortal, TCGA dataset) wherein they are associated with inferior outcomes. The present identification of a U2AF1 mutation also supports a diagnosis of AML-MR (ELN Guidelines - AML 2022, NCCN Guidelines - AML 2023). U2AF1 mutations are observed in 8-12% of MDS cases where have been associated with inferior outcomes (NCCN Guidelines - MDS 2023). U2AF1 mutations are more common in patients with MF compared to those with ET and are generally not found in patients with PV (Delic (2016) PMID:27447873). In MPN, U2AF1 mutations are associated with an inferior outcome (NCCN Guidelines - MPN 2023).	NA
chrX	47193828	47215128	plus	No	No	Yes	No	No	UBA1	LOF	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr11	119355214	119381690	minus	No	No	Yes	No	No	USP2	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr3	39052015	39096664	plus	No	No	Yes	No	No	WDR48	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr11	32387774	32435539	minus	Core	No	Yes	Yes	Yes	WT1	LOF	1B for MDS, 3A for AML, MPN	None	NA	NA	NA	NA	NA	NA	AML, MDS, MPN	In myeloid malignancies, disruption of WT1 promotes stem cell proliferation and leukemic transformation (Pronier (2018) PMID:30064973; Rampal (2016) PMID:27252512). WT1 mutations have been identified in approximately 10% of AML patients. Conflicting data exists regarding the prognostic or predictive significance of WT1 mutations in AML (Rampal (2016) PMID:27252512; Marcucci (2011) PMID:21220609). WT1 mutations are uncommon in MDS patients. In MDS, WT1 mutations are associated with a poor prognosis (NCCN Guidelines - MDS 2023) and with a higher risk of transformation to secondary AML (Makishima (2017) PMID:27992414). WT1 mutations are rarely identified in MPN patients. The predictive and prognostic significance of WT1 mutations in MPNs remain uncertain.	NA
chr13	19958726	20089115	plus	No	No	Yes	No	No	ZMYM2	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr6	87155564	87265943	plus	No	No	Yes	No	No	ZNF292	FUS	2	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
chr12	6666477	6689572	minus	No	Yes	Yes	No	No	ZNF384	Gene rearrangement	1A	None	NA	Classification of B-ALL; B-ALL with ZNF384(362) rearrangement; Provisional entity: B-ALL, ZNF384 rearranged-like, (ICC, PMID: 35767897).	EP300 (most common and good prognosis), TCF3, TAF15, CREBBP	NA	NA	NA	NA	Variable	NA
chrX	15790156	15830694	plus	Core	Yes	Yes	Yes	Yes	ZRSR2	Mutated gene	1A	None	Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897).	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)	NA
Complex	NA	NA	NA	NA	NA	Yes	NA	NA	NA	NA	1A	None	NA	NA	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	In the context of AML the presence of a complex genome (i.e. karyotype) in associated with an adverse prognosis (PMID: 35797463).	NA
chr13	0	114364328	NA	NA	NA	Yes	NA	NA	-13 or del(13q)	Loss	1A	None	Defining cytogenetic abnormalities in acute myeloid leukaemia, myelodysplasia-related.; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	NA	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	NA	NA
chr7	0	159345973	NA	NA	NA	Yes	NA	NA	-7 or del(7q)	Loss	1A	None	Defining cytogenetic abnormalities in acute myeloid leukaemia, myelodysplasia-related.; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	NA	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Optical Genome Mapping detected a deletion 7q or monosomy 7 in [%] of the sample. In the context of a diagnosis of AML, deletion 7q is associated with an intermediate prognosis, monosomy 7 is associated with an adverse prognosis (PMID:35797463)	NA
chr11	53400000	135086622	NA	NA	NA	Yes	NA	NA	del(11q)	Deletion	1A	None	Defining cytogenetic abnormalities in acute myeloid leukaemia, myelodysplasia-related.; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	NA	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	NA	NA
chr12	0	35500000	NA	NA	NA	Yes	NA	NA	del(12p)	Deletion	1A	None	Defining cytogenetic abnormalities in acute myeloid leukaemia, myelodysplasia-related.; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	NA	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Optical Genome Mapping detected a deletion 12p overlapping the region with the ETV6 gene, in [%] of the sample.	NA
chr17	0	25100000	NA	NA	NA	Yes	NA	NA	del(17p)	Deletion	1A	None	Defining cytogenetic abnormalities in acute myeloid leukaemia, myelodysplasia-related.; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	NA	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Optical Genome Mapping detected a deletion 17p overlapping the region with the TP53 gene, in [%] of the sample. Deletion of TP53 is often seen in complex karyotypes and is associatd with a poor prognosis (PMID: 35797463).	NA
chr17	pter	qter	NA	NA	NA	Yes	NA	NA	monosomy 17	Loss	1A	None	NA	NA	NA	NA	NA	NA	NA	Optical Genome Mapping detected a monosomy 17 in [%] of the sample. Monosomy of chromosome 17 is often seen in complex karyotypes and is associatd with a poor prognosis (PMID: 35797463).	NA
chr5	48800000	181538259	NA	NA	NA	Yes	NA	NA	del(5q) or -5	Deletion	1A	None	Classification and defining features of myelodysplastic neoplasms (MDS).; MDS with low blasts and isolated 5q deletion (MDS-5q). Premalignant clonal cytopenias and myelodysplastic syndromes; Myelodysplastic syndrome with del(5q) (WHO, PMID: 35732831).	NA	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Optical Genome Mapping detected a deletion 5q or monosomy 5 in [%] of the sample. In the context of a diagnosis of AML, this is associated with an adverse prognosis (PMID:35797463)	NA
chrX	68500000	76800000	NA	NA	NA	Yes	NA	NA	idic(X)(q13)	Isodicentric	1A	None	Defining cytogenetic abnormalities in acute myeloid leukaemia, myelodysplasia-related.; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	NA	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Optical Genome Mapping detected a isodicentric chromosome Xq in [%] of the sample. idic(Xq) is recurrent abnormality in the context of myeloid neoplasia and in the context of a diagnosis of AML and is associated with an intermediate prognosis (PMID: 35797463)	NA
chr16	10400000	74100000	NA	NA	NA	Yes	NA	NA	inv(16)(p13.1q22)	Inversion	1A	None	NA	Classification of AML with percentage of blasts required for diagnosis; AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11 = 10% (ICC, PMID: 35767897).	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	NA	NA
chr3	126100000	171200000	NA	NA	NA	Yes	NA	NA	inv(3)(q21.3q26.2)	Inversion	1A	None	NA	Classification of AML with percentage of blasts required for diagnosis; AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2; MECOM(EVI1) = 10% (ICC, PMID: 35767897).	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	NA	NA
chr17	25100000	83257441	NA	NA	NA	Yes	NA	NA	Iso(17q)	Isochromosome	1A	None	Defining cytogenetic abnormalities in acute myeloid leukaemia, myelodysplasia-related.; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	NA	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Optical Genome Mapping detected a loss of chromosome material on chromosome 17p with a concomitant copy number gain on chromosome 17q. This pattern is consisent with an isochromosome 17q with in [%] of the sample. Note that a 17p copy number reducation is consistent with loss of a TP53 allele.	NA
chr8	pter	qter	NA	NA	NA	Yes	NA	NA	trisomy 8	Gain	1A	None	NA	NA	NA	NA	NA	NA	MDS/AML (10-19%), AML (=20% blasts)	Optical Genome Mapping detected a trisomy 8 with a fractional copy number of []. Trisomy for chromosome 8 is recurrent abnormality in both de novo and treatment-related leukemia. In the context of a diagnosis of AML, trisomy 8 is associated with an intermediate prognosis (PMID:35797463)	NA
chr20	20q	20q	NA	NA	NA	Yes	NA	NA	Deletion 20q	Deletion	1A	None	NA	NA	NA	NA	NA	NA	NA	NA	NA
